School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200003, China.
Shanghai Skin Disease Hospital, Shanghai 200040, China.
Int J Environ Res Public Health. 2021 Oct 19;18(20):10980. doi: 10.3390/ijerph182010980.
BACKGROUND: Ensuring adherence guarantees the efficacy of pre-exposure prophylaxis (PrEP). METHODS: We conducted a cross-sectional study among 816 sexually transmitted infection (STI) patients in Shanghai. The questionnaire included self-reported demographic characteristics, self-administered items on adherence to free oral PrEP, and PrEP uptake behavior measurement. We conducted item analysis, reliability analysis, validity analysis and receiver operating characteristic (ROC) curve analysis. RESULTS: Not all items were considered acceptable in the item analysis. The questionnaire had a McDonald's ω coefficient of 0.847. The scale-level content validity index (CVI) was 0.938 and the item-level CVI of each item ranged from 0.750 to 1. In exploratory factor analysis, we introduced a four-factor model accounting for 79.838% of the aggregate variance, which was validated in confirmatory factor analysis. Adding PrEP adherence questionnaire scores contributed to prediction of PrEP uptake behavior ( < 0.001) in regression analysis. The maximum area under the ROC curve was 0.778 (95% IC: 0.739-0.817). CONCLUSION: The PrEP adherence questionnaire presented psychometric validation among STI patients.
背景:确保依从性可保证暴露前预防(PrEP)的疗效。
方法:我们在上海的 816 名性传播感染(STI)患者中进行了一项横断面研究。问卷包括自我报告的人口统计学特征、自我管理的免费口服 PrEP 依从性项目以及 PrEP 摄取行为测量。我们进行了项目分析、信度分析、效度分析和受试者工作特征(ROC)曲线分析。
结果:并非所有项目在项目分析中都被认为是可接受的。问卷的 McDonald's ω系数为 0.847。量表水平的内容效度指数(CVI)为 0.938,每个项目的项目水平 CVI 范围为 0.750 至 1。在探索性因子分析中,我们引入了一个可解释总方差 79.838%的四因素模型,该模型在验证性因子分析中得到了验证。在回归分析中,增加 PrEP 依从性问卷评分有助于预测 PrEP 摄取行为(<0.001)。ROC 曲线下的最大面积为 0.778(95%CI:0.739-0.817)。
结论:PrEP 依从性问卷在 STI 患者中具有心理测量学验证。
Int J Environ Res Public Health. 2021-10-19
Int J Infect Dis. 2018-8-17
Curr HIV/AIDS Rep. 2019-12
Clin Infect Dis. 2020-7-27
Addict Behav. 2018-7-21
Int J Gynaecol Obstet. 2018-4-24
JAMA. 2018-3-27
Curr HIV/AIDS Rep. 2018-4